Related Experiment Video
Updated: Jan 8, 2026

05:19
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
3.2K
Development and Validation of a Cross-Device Platform for Anhedonia Trend Visualization by Using Ecological Momentary
Yen-Chung Ho1, Chia-Ling Fang1, Yung-Chieh Ching1
1School of Nursing, College of Nursing, Asia University, Taichung, Taiwan.
JMIR Research Protocols
|December 18, 2025
Summary
This study developed a platform for monitoring anhedonia using Ecological Momentary Assessment (EMA) and Simple Moving Averages (SMA). The platform visualizes trends for early detection of anhedonia symptoms in individuals.
Area of Science:
- Psychiatry and Mental Health
- Digital Health
- Data Science
Background:
- Anhedonia is a key symptom of depressive disorders, but real-time individual monitoring is limited.
- Ecological Momentary Assessment (EMA) allows for high-frequency data collection.
- Simple Moving Averages (SMA) can smooth daily signals for early trend detection.
Purpose of the Study:
- To develop and validate a cross-device platform for individual anhedonia monitoring using EMA-SHAPS.
- To assess the platform's feasibility, usability, data quality, and initial analytical validity.
- To inform a subsequent evaluation of the platform's clinical utility.
Main Methods:
- A single-arm methodological pilot study involving approximately 24 adults (clinical and nonclinical cohorts).
- Participants completed 30 days of daily EMA-SHAPS assessments.
- Primary outcomes included feasibility (adherence, missingness, timing) and usability (System Usability Scale, qualitative feedback).
Main Results:
- The protocol specifies design, recruitment, and data rules for computing moving averages.
- Recruitment for the feasibility pilot is scheduled for March 2026.
- Feasibility metrics, usability indices, and parameter estimates will refine alert logic for future evaluations.
Conclusions:
- Combining EMA-SHAPS with SMA trend visualizations may offer interpretable early-warning indicators for anhedonia.
- This pilot study will provide essential feasibility, usability, and analytical data.
- The findings will support a future controlled evaluation of the platform's clinical utility.

